N. Chaudhuri (Manchester (Greater Manchester), United Kingdom), C. Valenzuela (Alcobendas (Madrid), Spain), A. Morais (Maia, Portugal), S. Ohshimo (Hiroshima, Japan)
Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON
U. Costabel (Essen, Germany), M. Kreuter (Heidelberg, Germany), J. Song (Seul, Republic of Korea), J. Huggins (Charleston, South Carolina, United States of America), B. Wallaert (Lille, France), W. Stansen (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), B. Crestani (Paris, France)
|   |
Factors influencing Idiopathic Pulmonary Fibrosis (IPF) anti-fibrotic decisions in a single UK centre; patient and physician perspectives
A. Papadopoulos (Oxford, United Kingdom), S. Zannetos (Nicosia, Cyprus), R. Hoyles (Oxford, United Kingdom)
| |
Investigation burden in patients with fibrotic interstitial lung disease in their terminal admission
H. Guo (Melbourne, Australia), J. Mann (Melbourne, Australia), N. Smallwood (Melbourne, Australia), N. Goh (Melbourne, Australia)
| |
Three-centre study (DZL) to investigate the effects of three-month whole-body vibration training on muscle strength, lung function, health-related quality of life and inflammation markers in patients with pulmonary fibrosis.
A. Koczulla (Marburg, Germany), T. Boeselt (Marburg, Germany), J. Koelpin (Marburg, Germany), C. Nell (Marburg, Germany), F. Kaufhold (Heidelberg, Germany), C. Vogelmeier (Marburg, Germany), F. Herth (Heidelberg, Germany), P. Alter (Marburg, Germany), M. Veith (Marburg, Germany), T. Greulich (Marburg, Germany), C. Kaehler (Wangen, Germany), M. Kreuter (Heidelberg, Germany)
| |
Lessons learned when recruiting for an early Idiopathic Pulmonary Fibrosis (IPF) palliative care intervention
K. Lindell (Pittsburgh, United States of America), M. Nouraie (Pittsburgh, United States of America), S. Klein (Pittsburgh, United States of America), M. Klesen (Pittsburgh, United States of America), K. Gibson (Pittsburgh, United States of America), D. Kass (Pittsburgh, United States of America), M. Rosenzweig (Pittsburgh, United States of America)
| |
Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?
H. Morris (Manchester, United Kingdom), T. Marshall (Manchester, United Kingdom), K. Zakis (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), C. Hayton (Manchester, United Kingdom), P. Rivera Ortega (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), J. Blaikley (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom)
| |
Team support with pharmacists improved tolerability of antifibrotic agents for pulmonary fibrosis.
M. Kogo (Kobe, Japan), Y. Satsuma (Kobe, Japan), K. Kusuda (Kobe, Japan), H. Ikesue (Kobe, Japan), R. Mori (Kobe, Japan), D. Fujimoto (Kobe, Japan), K. Nagata (Kobe, Japan), A. Nakagawa (Kobe, Japan), R. Tachikawa (Kobe, Japan), K. Otsuka (Kobe, Japan), K. Tomii (Kobe, Japan)
| |
Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis.
A. Belz (Chorzow, Poland), P. Debowska (Katowice, Poland), J. Warzecha (Zabrze, Poland), A. Gasiorek (Zabrze, Poland), D. Galczynska (Zabrze, Poland), S. Czyz (Zabrze, Poland), B. Ziaja (Zabrze, Poland), D. Jastrzebski (Zabrze, Poland), D. Ziora (Zabrze, Poland)
| |
Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
M. Kato (Tokyo, Japan), T. Nakamura (Tokyo, Japan), K. Kono (Tokyo, Japan), M. Haraguchi (Tokyo, Japan), T. Yamada (Tokyo, Japan), H. Ihara (Tokyo, Japan), F. Takahashi (Tokyo, Japan), K. Takahashi (Tokyo, Japan)
| |
Benefits of a pilot program of supervised exercise training in Idiopathic Pulmonary Fibrosis
J. Bordas Martinez (Barcelona, Spain), J. Palma Lopez (Barcelona, Spain), M. Sampere Aymerich (Barcelona, Spain), A. Bachs Salvado (Barcelona, Spain), L. Planas Cerezales (Barcelona, Spain), I. Callorda Boniatti (Barcelona, Spain), F. Lopez Beltran (Barcelona, Spain), R. Planas Balague (Barcelona, Spain), J. Dorca Sargatal (Barcelona, Spain), M. Molina Molina (Barcelona, Spain), V. Vicens Zygmunt (Barcelona, Spain)
| |
Long-term (4 years) experience of Nintedanib in IPF patients in Crete: A real life data study
K. Antoniou (Herakleion, Greece), A. Trachalaki (Herakleion, Greece), E. Vasarmidi (Herakleion, Greece), G. Margaritopoulos (London, United Kingdom), G. Papastratigakis (Herakleion, Greece), E. Bibaki (Herakleion, Greece), E. Stamataki (Herakleion, Greece), G. Meletis (Herakleion, Greece), N. Tzanakis (Herakleion, Greece)
| |
Palliative and symptomatic care of patients with fibrotic interstitial lung disease
J. Mann (Melbourne, Australia), H. Guo (Melbourne, Australia), N. Goh (Melbourne, Australia), N. Smallwood (Melbourne, Australia)
| |
Multidisciplinary management of interstitial lung diseases in a tertiary centre: A prospective study.
C. Biglia (Bruxelles, Belgium), B. Ghaye (Bruxelles, Belgium), G. Reychler (Bruxelles, Belgium), V. Lacroix (Bruxelles, Belgium), F. Tamirou (Bruxelles, Belgium), D. Hoton (Bruxelles, Belgium), T. Pieters (Bruxelles, Belgium), A. Froidure (Bruxelles, Belgium)
| |
Idiopathic Pulmonary Fibrosis (IPF): Should it be all about the FVC?
S. Boot (Leeds, United Kingdom), L. Horgan (Leeds, United Kingdom), L. Flint (Leeds, United Kingdom), T. Sutherland (Leeds, United Kingdom), P. Beirne (Leeds, United Kingdom)
| |
A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis
M. Naqvi (London, United Kingdom), G. D'Ancona (London, United Kingdom), A. West (London, United Kingdom)
| |
Real-life efficacy of Pirfenidone in a cohort of patients with IPF in Northern Greece
S. Kotoulas (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), I. Organtzis (Thessaloniki, Greece), G. Pitsiou (Thessaloniki, Greece), A. Papaioannou (Thessaloniki, Greece), C. Euthymiou (Thessaloniki, Greece), I. Stanopoulos (Thessaloniki, Greece), V. Mourouzidou (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece)
| |
Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis
L. Schwarzkopf (Neuherberg, Germany), S. Witt (Neuherberg, Germany), J. Waelscher (Heidelberg, Germany), M. Polke (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
| |
Experience of patients treated with nintedanib in the Community of Madrid. REFIPIMAD Registry
M. Nieto Barbero (Madrid, Spain), L. Gómez Carrera (Madrid, Spain), M. Rodríguez Nieto (Madrid, Spain), Á. Casanova Espinosa (Madrid, Spain), R. Laporta Hernández (Madrid, Spain), B. López-Muñiz Ballesteros (Madrid, Spain), C. Valenzuela (Madrid, Spain), T. Bilbao-Goyoaga Arenas (Madrid, Spain), G. Mora Ortega (Madrid, Spain), M. Río Ramírez (Madrid, Spain)
| |
Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial
S. Homma (Tokyo, Japan), Y. Kondoh (Aichi, Japan), M. Kato (Tokyo, Japan), T. Hoshino (Fukuoka, Japan), H. Mukae (Nagasaki, Japan), M. Bando (Tochigi, Japan), T. Suda (Hamamatsu, Japan), T. Kido (Fukuoka, Japan), Y. Tanino (Fukushima, Japan), T. Kishaba (Okinawa, Japan), N. Hattori (Hiroshima, Japan), Y. Taguchi (Nara, Japan), T. Saitoh (Ibaraki, Japan), Y. Nishioka (Tokushima, Japan), K. Kuwano (Tokyo, Japan), K. Kishi (Tokyo, Japan), N. Inase (Tokyo, Japan), S. Sasaki (Chiba, Japan), H. Takizawa (Tokyo, Japan), T. Johkoh (Osaka, Japan), F. Sakai (Saitama, Japan), S. Sakamoto (Tokyo, Japan)
| |